Pharmafile Logo
Pharmafocus logo
Advanced Search

Valeant

Showing 15 posts of 90 posts found.

Allergan image

Allergan and Valeant trade blows as shareholder meeting looms

November 6, 2014
Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner

Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …

News
Valeant image

Valeant goes hostile over Allergan hunt

June 19, 2014
Sales and Marketing Allergan, Botox, Valeant, hostile, takeover

Valeant Pharmaceuticals has turned hostile in its bid to acquire Botox maker Allergan by employing strong-arm tactics in an attempt …

News
Allergan image

Allergan rejects Valeant – again

June 11, 2014
Research and Development, Sales and Marketing Allergan, Botox, Valeant, pershing, pharma

Allergan and Valeant Pharmaceuticals International are continuing their stately dance around one another – and in the latest move the …

News
Allergan image

Valeant ‘substantially undervalues’ Allergan

May 13, 2014
Sales and Marketing Allergan, Botox, Pfizer, Valeant, buyout, merger

Allergan’s board has issued a defiant, unanimous rejection of the multi-billion dollar takeover offer made public by Valeant last month. In …

News
Allergan image

Valeant makes $45.7 billion Allergan offer

April 23, 2014
Sales and Marketing Allergan, Botox, GSK, Novartis, Pfizer, Valeant, merger, pershing

In the latest proposal in a flurry of merger and acquisition activity in the pharma sector, Valeant Pharmaceuticals International wants …

News

Valeant to buy B+L for $8.7 billion

May 29, 2013
Sales and Marketing B+L, Valeant

Canadian firm Valeant Pharmaceuticals International is to buy Bausch + Lomb in an $8.7 billion deal which will see the …

News
FDA image

FDA rejects Valeant’s efinaconazole on packaging grounds

May 29, 2013
Manufacturing and Production FDA, Valeant

Valeant Pharmaceuticals has had its application to market antifungal candidate efinaconazole turned down by the FDA because of issues related …

News
Valeant image

Valeant shuts plant in Brazil, second to follow

January 8, 2013
Manufacturing and Production Brazil, Medicis, Valeant

Canadian firm Valeant Pharmaceuticals has closed down one of its facilities in Brazil and will shutter a second in the …

News

Valeant to buy dermatogy firm Medicis

September 4, 2012
Sales and Marketing Valeant

Speciality pharma company Valeant is to acquire dermatology-focused Medicis for $2.6 billion.Medicis’ portfolio includes ‘cosmaceutical’ prescription brands such as Solodyn, …

News
Sanofi

Sanofi sells dermatology unit for $425m

July 11, 2011
Manufacturing and Production, Sales and Marketing Canada, Dermik, Sanofi, Valeant, dermatology

Sanofi has sold its Canadian dermatology unit Dermik for $425 million in order to concentrate on key growth areas like …

News
GlaxoSmithKline

GSK’s epilepsy treatment Potiga wins US approval

June 13, 2011
Sales and Marketing GSK, Potiga, Trobalt, Valeant, epilepsy

The FDA has approved GlaxoSmithKline and Valeant’s epilepsy treatment Potiga, but the drug will require further review before it can …

News
Cephalon

Cephalon accepts Teva’s $6.8 billion white knight bid

May 3, 2011
Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics

Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …

News

GSK and Valeant’s epilepsy treatment approved

April 8, 2011
Sales and Marketing GSK, Trobalt, Valeant, epilepsy

The European Commission has granted marketing authorisation for Trobalt, the new epilepsy drug from GSK and Valeant. Trobalt (retigabine) has …

News
Cephalon

Valeant makes $5.7 billion hostile bid for Cephalon

March 31, 2011
Research and Development, Sales and Marketing Cephalon, Valeant

Valeant has made a hostile bid for Cephalon, but analysts believe its offer is too low for the deal to …

News

Manufacturing news in brief

April 6, 2010
Manufacturing and Production NIB, Valeant, Warner Chilcott, baxter

 This week’s round-up of recent developments in the pharmaceutical manufacturing arena sees a new facility build for Ireland’s HKPB and …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024